Compass Therapeutics (NASDAQ:CMPX) CAO Buys 20,000 Shares of Stock

Key Points

• Insider purchase: Chief Accounting Officer Neil Lerner bought 20,000 Compass Therapeutics shares at an average price of $0.92, increasing his direct ownership to 420,000 shares.
• Weak stock and earnings performance: CMPX opened at $0.90, near its 52-week low of $0.90, while the company reported a quarterly loss of $0.13 per share, missing estimates by $0.02.
• Mixed but generally favorable sentiment: Analysts’ consensus rating is “Moderate Buy,” with an average price target of $10.21, although some firms recently downgraded the stock and institutional investors own 68.43% of shares.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) CAO Neil Lerner acquired 20,000 shares of the company's stock in a transaction on Thursday, October 1st. The shares were bought at an average cost of $0.92 per share, with a total value of $18,400.00. Following the acquisition, the chief accounting officer directly owned 420,000 shares in the company, valued at approximately $386,400. The trade was a 5.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Neil Lerner also recently made the following trade(s):

• On Thursday, September 24th, Neil Lerner purchased 2,500 shares of Compass Therapeutics stock. The shares were purchased at an average price of $1.14 per share, with a total value of $2,850.00.

Compass Therapeutics Stock Performance

CMPX stock opened at $0.90 on Friday. The firm has a fifty day moving average price of $2.00 and a 200 day moving average price of $2.74. Compass Therapeutics, Inc. has a fifty-two week low of $0.90 and a fifty-two week high of $6.88. The firm has a market cap of $162.28 million, a PE ratio of -2.25 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities analysts predict that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Therapeutics in a report on Friday, July 17th. Lifesci Capital lowered Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 22nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Piper Sandler upped their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Finally, Wall Street Zen downgraded shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Compass Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $10.21.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Compass Therapeutics during the 2nd quarter worth approximately $24,707,000. BVF Inc. IL raised its holdings in shares of Compass Therapeutics by 63.5% during the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company's stock worth $41,697,000 after acquiring an additional 3,014,842 shares during the period. Palo Alto Investors LP purchased a new position in Compass Therapeutics during the second quarter worth about $12,771,670. Sofinnova Investments Inc. lifted its holdings in Compass Therapeutics by 65.9% in the fourth quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company's stock valued at $18,072,000 after acquiring an additional 1,336,560 shares during the last quarter. Finally, NEXTBio Capital Management LP acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $5,982,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company's research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.